Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
Breast J ; 23(6): 670-676, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28481477

RESUMO

We report the outcomes of the European prospective study on prepectoral breast reconstruction using preshaped acellular dermal matrix for complete breast implant coverage. Seventy-nine patients were enrolled between April 2014 and August 2015 all over Europe using a single protocol for patient selection and surgical procedure, according to the Association of Breast Surgery and British Association of Plastic Reconstructive and Aesthetic Surgeons joint guidelines for the use of acellular dermal matrix in breast surgery. The preshaped matrix completely wraps the breast implant, which is placed above the pectoralis major, without detaching the muscle. A total of 100 prepectoral breast reconstructions with complete implant coverage were performed. This series, with mean follow-up of 17.9 months, had two cases of implant loss (2.0%) including one necrosis of the nipple and one wound breakdown (1.0% respectively). No implant rotations were observed. Good cosmetic outcomes were obtained with natural movement of the breasts and softness to the touch; none of the patients reported experiencing pain or reduction in the movements of the pectoralis major muscle postoperatively. The use of preshaped acellular dermal matrix for a complete breast implant coverage in selected patients is safe and gives satisfactory results, both from the aesthetic view point and the low postoperative complication rates. Further studies reporting long-term outcomes are planned.


Assuntos
Neoplasias da Mama/cirurgia , Mamoplastia , Músculos Peitorais/cirurgia , Derme Acelular , Adulto , Idoso , Neoplasias da Mama/patologia , Europa (Continente) , Feminino , Humanos , Mastectomia , Pessoa de Meia-Idade , Complicações Pós-Operatórias , Estudos Prospectivos
3.
J Orthop Trauma ; 33(1): e24-e26, 2019 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-30086045

RESUMO

Negative pressure wound therapy, a tool widely applied to treat lower limb traumas, is useful in reconstructive procedures. However, obtaining an airtight vacuum seal when using a negative pressure dressing around an external fixation device can be complicated and time-consuming. The plastic drape seldom adheres to screws, pins, or wires and, as such, the vacuum seal is jeopardized. In surgical departments, colostomy paste is widely used, readily available, and applied where pins and wires make contact with the plastic drape. It is a fast, practical, and inexpensive method of preventing air leakage. In conclusion, to obtain an airtight seal between the skin and an external fixation device, colostomy paste may be used to ensure an optimal tight seal, even for complex and extended wounds, for 3-5 days without complications or the requirement for additional dressing changes. Furthermore, it is inexpensive, readily available, simple to use, and quick to apply.


Assuntos
Fixadores Externos , Fixação de Fratura/instrumentação , Tratamento de Ferimentos com Pressão Negativa/métodos , Fraturas da Tíbia/cirurgia , Estudos de Coortes , Humanos , Tratamento de Ferimentos com Pressão Negativa/economia
4.
Melanoma Res ; 25(5): 443-6, 2015 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-26110554

RESUMO

Many genetic alterations, including predisposing or somatic mutations, may contribute toward the development of melanoma. Although CDKN2A and CDK4 are high-penetrance genes for melanoma, MC1R is a low-penetrance gene that has been associated most consistently with the disease. Moreover, BRAF is the most frequently somatically altered oncogene and is a validated therapeutic target in melanoma. This paper reports a case of multiple primary melanoma with germline CDK4 mutation, MC1R variant, and somatic BRAF mutation in nine out of 10 melanomas, indicating that a common pathogenesis, because of a predisposing genetic background, may be shared among distinct subsequent melanomas of probable clonal origin. After 3 months of targeted therapy with BRAF inhibitor, our patient developed resistance with rapid progression of the disease leading to death. This is the first case in which early resistance to BRAF inhibitor has been reported in a patient with CDK4 germline mutation.


Assuntos
Quinase 4 Dependente de Ciclina/genética , Mutação em Linhagem Germinativa , Melanoma/genética , Neoplasias Primárias Múltiplas/genética , Proteínas Proto-Oncogênicas B-raf/genética , Neoplasias Cutâneas/genética , Adulto , Resistencia a Medicamentos Antineoplásicos/genética , Evolução Fatal , Predisposição Genética para Doença , Humanos , Indóis/uso terapêutico , Masculino , Melanoma/tratamento farmacológico , Neoplasias Primárias Múltiplas/tratamento farmacológico , Mutação Puntual , Proteínas Proto-Oncogênicas B-raf/antagonistas & inibidores , Neoplasias Cutâneas/tratamento farmacológico , Sulfonamidas/uso terapêutico , Vemurafenib
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA